Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment providing unprecedented clinical benefits. However, many patients do not respond to ICIs as monotherapy or develop resistance. Combining ICI-based immunotherapy with chemotherapy is a promising strategy to inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Alessandra, Lucarini, Valeria, Macchia, Iole, Sestili, Paola, Buccione, Carla, Donati, Simona, Ciccolella, Maria, Sistigu, Antonella, D’Urso, Maria Teresa, Pacca, Anna Maria, Cardarelli, Enrico, Mattei, Fabrizio, Proietti, Enrico, Schiavoni, Giovanna, Bracci, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226952/
https://www.ncbi.nlm.nih.gov/pubmed/32290265
http://dx.doi.org/10.3390/cells9040940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226952/
https://www.ncbi.nlm.nih.gov/pubmed/32290265
http://dx.doi.org/10.3390/cells9040940

Ejemplares similares